Glatiramer acetate consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons. It is an immunomodulator, licensed in much of the world for reduced frequency of relapses in relapsing-remitting multiple sclerosis
Relatively few head-to-head studies have been conducted among the BRACE therapies and discussion here is confined to those involving IFN beta-1b: versus IFN beta-1a IM, the Independent Comparison of Interferons (INCOMIN) trial ; versus IFN beta-1a SC ; versus IFN beta-1a both IM and SC ; and versus GA, the Betaferon
Efficacy Yielding Outcomes of a New Dose (BEYOND; ClinicalTrials.gov #NCT00099502) trial  and the Betaseron
in Multiple Sclerosis with Triple-Dose Gadolinium and 3-Tesla MRI Endpoints (BECOME; ClinicalTrials.gov #NCT00176592) trial .
More recently, in the BECOME (Betaseron
in MS with Triple-Dose Gadolinium and 3-T MRI Endpoints) study, the effect of IFN-β-1b and GA on new active lesions was tested on the 3 T optimized protocol (3 T MRI scanner, a triple dose of Gd, with a 20-min scanning time delay after Gd injection) in 75 patients with relapsing-remitting (RR) MS who underwent serial monthly MRI scans over 12 months .